Strengthening Contract Research Capabilities in Oncology and the Central Nervous System
First written in FY2016. 2 of 5 entries say "Restated". Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024RaisedAnnual report
「Pharmaceutical companies’ priority development areas are expanding beyond oncology, central nervous system disorders and immunology, where the Company already has extensive experience, to include ophthalmology, dermatology and rare diseases. To provide proposals that match customer needs in these new modalities and disease areas and conduct high-quality clinical development in a short period, the Group will strengthen collaboration with external experts and medical institutions and actively gather information, in addition to applying the clinical development expertise accumulated in highly challenging areas.」
The Company is expanding its coverage beyond traditional areas such as oncology and central nervous system disorders to ophthalmology, dermatology, rare diseases and new drug-discovery modalities. - FY2020RestatedAnnual report
「The Company has established specialized departments and provides contract research services in the following areas, where pharmaceutical companies are expanding their development pipelines to address unmet medical needs.」
The Company continues to operate a structure with specialized departments for oncology and central nervous system disorders, staffed by experienced managers and CRAs. - FY2018RestatedAnnual report
「To address the increasing number of development products in oncology and central nervous system disorders in recent years, the Company is strengthening its contract research structure through recruitment, training and organizational changes.」
The Company continues to report strengthening its contract research structure in oncology and central nervous system disorders through personnel, training and organizational changes. - FY2017AdvancedAnnual report
「The Company has established specialized departments and provides contract research services in the following areas, where pharmaceutical companies are expanding their development pipelines to address unmet medical needs.」
The Company has established specialized departments for oncology and central nervous system disorders and has created a structure for concentrating expertise by assigning experienced managers and CRAs. - FY2016First statedAnnual report
「To address the increasing number of development products in oncology and central nervous system disorders in recent years, the Company is strengthening its contract research structure through recruitment, training and organizational changes.」
The Company identifies oncology and central nervous system disorders as priority areas requiring specialized expertise and plans to address them through its personnel, training and organizational structure.